Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) vs Enlivex Therapeutics Ltd. (ENLV)
A side-by-side comparison of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares and Enlivex Therapeutics Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
$2.25HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
ENLV
Enlivex Therapeutics Ltd.
$0.36HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CUPR vs ENLV
growth of $100 · dividends reinvested · last 1yCUPR -93.2% (-93.2%/yr)ENLV -97.3% (-97.3%/yr)CUPR compounded faster over this window
CUPR ENLV
CUPR vs ENLV: by the numbers
- •ENLV is the larger company ($6M vs $6M market cap).
- •Both run net losses; ENLV's is the smaller (0.00% vs -9366.75% net margin).
Metrics side by side
Valuation
| Metric | CUPR | ENLV |
|---|---|---|
| P/E ratio | N/A | 0.00 |
| P/B ratio | 1.54 | 0.00 |
Profitability
| Metric | CUPR | ENLV |
|---|---|---|
| Gross margin | -1.29% | 0.00% |
| Operating margin | -9154.62% | 0.00% |
| Net margin | -9366.75% | 0.00% |
| ROE | -92.44% | 105.35% |
| ROIC | -84.15% | -0.32% |
Growth (annualized)
| Metric | CUPR | ENLV |
|---|---|---|
| Total return CAGR (5Y) | N/A | -69.81% |
Go deeper
Dig into the metrics
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares ROEEnlivex Therapeutics ROECuprina Holdings (Cayman) Limited Class A Ordinary Shares operating marginEnlivex Therapeutics operating marginCuprina Holdings (Cayman) Limited Class A Ordinary Shares revenue growthEnlivex Therapeutics revenue growthCuprina Holdings (Cayman) Limited Class A Ordinary Shares free cash flowEnlivex Therapeutics free cash flow
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares & Enlivex Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.